Sepsis Guidelines: SSC 2026 (Updated)

Breaking: The Surviving Sepsis Campaign (SSC) 2026 Guidelines - for both adults (129 recommendations) and children (61 recommendations) - were published in April 2026 in Critical Care Medicine / Intensive Care Medicine and formally announced at SCCM2026 in Chicago, endorsed by 24 (adult) and 14 (pediatric) professional organisations. These supersede SSC 2021.

Definition (Sepsis-3, still current)

• Sepsis: Life-threatening organ dysfunction caused by a dysregulated host response to infection. Operationalized as SOFA score ≥ 2 above baseline.
• Septic shock: A subset of sepsis with circulatory and cellular/metabolic dysfunction; requires vasopressors to maintain MAP ≥ 65 mmHg AND serum lactate > 2 mmol/L despite adequate volume resuscitation. Hospital mortality > 40%.

SSC 2026: Adult Recommendations

1. Screening & Recognition

• Performance improvement programs: Hospitals should use sepsis performance improvement protocols (strong recommendation).
• Screening tools: Use validated tools (e.g., NEWS, qSOFA) to screen for sepsis in at-risk patients, including prehospital settings (conditional).
• Biomarkers: Procalcitonin (PCT) and CRP can support diagnosis; lactate ≥ 2 mmol/L identifies higher-risk patients.
• Blood cultures: Obtain ≥ 2 sets before antibiotics whenever feasible without meaningfully delaying therapy.
• Lactate: Measure serum lactate; repeat if initial > 2 mmol/L to guide resuscitation.

2. Initial Resuscitation

• Fluids: Begin IV crystalloid resuscitation promptly. The SSC 2026 moves away from a rigid 30 mL/kg protocol - use dynamic hemodynamic assessment (passive leg raise, pulse pressure variation, echocardiography) to guide fluid administration. For obese patients, calculate on adjusted body weight (not actual).
• Fluid type: Use balanced crystalloids (lactated Ringer's, Plasma-Lyte) over normal saline - reduces hyperchloremic acidosis risk.
• ROSE Framework (Resuscitation - Optimization - Stabilization - Evacuation): Give fluids early during shock; reassess dynamically; stop once shock resolves; actively de-resuscitate when congestion appears.

3. Vasopressors

• Timing (new 2026): Initial IV crystalloid fluid bolus first, then vasopressors if hypotension persists - but in unstable septic shock (mottled skin, altered mentation, profound hypotension), concurrent administration is appropriate. (Conditional, very low certainty - new recommendation)
• Route (new 2026): Start vasopressors peripherally rather than delaying until central venous access is secured. (Conditional, very low certainty)
• First-line agent: Norepinephrine remains first-line.
• Second-line: Vasopressin (to reduce norepinephrine dose or when norepinephrine alone is insufficient); epinephrine as an alternative.
• MAP target: ≥ 65 mmHg. New for 2026: In adults ≥ 65 years, an initial MAP target of 60-65 mmHg is conditionally recommended (lower target acceptable; no evidence for benefit of higher target in elderly).

4. Antimicrobial Therapy

• Timing: Administer IV antibiotics within 1 hour of septic shock recognition; within 3 hours for sepsis without shock.
• Empiric therapy: Broad-spectrum coverage appropriate to likely source, local resistance patterns, and patient risk factors (MRSA, Pseudomonas, fungi).
• De-escalation: Narrow antibiotics once culture/sensitivity results available - reduces resistance and adverse effects.
• Duration: Minimum effective course; procalcitonin-guided de-escalation/discontinuation is recommended to shorten duration.
• Source control: Identify and control the infectious source (drainage, debridement, device removal) as soon as medically and logistically feasible.

5. ICU Admission

• Admit patients requiring ICU-level care within 6 hours. (Conditional, low certainty - carried forward from 2021)

6. Corticosteroids

• In patients with septic shock who remain on vasopressors despite adequate resuscitation: hydrocortisone 200 mg/day (continuous infusion) or 50 mg IV every 6 hours.
• Steroids achieve faster shock reversal but have not demonstrated consistent mortality benefit across trials (ADRENAL, APROCCHSS). Monitor for hyperglycemia.

7. Ventilation (if intubated)

• Lung-protective ventilation: TV 6 mL/kg predicted body weight, Pplat ≤ 30 cmH₂O for ARDS.
• Prone positioning: ≥ 12-16 hours/day in moderate-severe ARDS (P/F < 150).
• Avoid routine use of high-frequency oscillatory ventilation (HFOV).

8. Other Adjuncts

• Glucose control: Target blood glucose 7.8-10 mmol/L (140-180 mg/dL); avoid hypoglycemia.
• DVT prophylaxis: Pharmacologic (LMWH preferred) unless contraindicated.
• Stress ulcer prophylaxis: In patients with risk factors for GI bleeding.
• Renal replacement therapy: No benefit to early initiation in AKI without other indications.
• IV immunoglobulin: Not routinely recommended.

Pediatric SSC 2026 (New)

• 5 strong recommendations
• 24 conditional recommendations
• 10 good practice statements
• 20 recommendations are new (compared to 2020)

Bundle Compliance (SEP-1 / Hour-1)

1. Measure lactate (repeat if > 2 mmol/L)
2. Obtain blood cultures before antibiotics
3. Administer broad-spectrum antibiotics
4. Begin rapid IV crystalloid (30 mL/kg) for hypotension or lactate ≥ 4 mmol/L
5. Apply vasopressors if patient is hypotensive during/after fluid resuscitation

What Changed from SSC 2021

Key Sources

• SSC 2026 Adult Guidelines: Prescott HC et al., Critical Care Medicine 2026. DOI: 10.1097/CCM.0000000000007075 (PMID: 41869847)
• SSC 2026 Pediatric Guidelines: Weiss SL et al., Pediatric Critical Care Medicine 2026. PMID: 41869844
• ESICM resource hub: survivingsepsis.org via ESICM
• Goldman-Cecil Medicine, 26e - Circulatory Therapy/Vasopressors sections
• Harrison's Principles of Internal Medicine 22e, Cardiovascular Dysfunction in Sepsis

Note from EM News (June 2026): A viewpoint critiques the 2026 SSC guidelines for favouring protocolized care despite evidence pointing toward individualized resuscitation. The debate between fixed bundle targets vs. adaptive strategies is ongoing.